3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
50
Lymphoma, Non-Hodgkin
45
Lymphoma
34
Lymphoma, Mantle-Cell
30
Lymphoma, Follicular
26
Multiple Myeloma
23
Hodgkin Disease
21
Lymphoma, Large B-Cell, Diffuse
18
Recurrence
13
Lymphoma, B-Cell, Marginal Zone
12
Leukemia
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Neoplasms
6
Lymphoma, T-Cell
5
Waldenstrom Macroglobulinemia
4
Lymphoma, Large-Cell, Anaplastic
4
Lymphoma, B-Cell
4
Leukemia, Myeloid, Acute
4
Leukemia, B-Cell
4
Breast Neoplasms
4
Small Cell Lung Carcinoma
3
Sezary Syndrome
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms, Plasma Cell
3
Myelodysplastic Syndromes
3
Mycosis Fungoides
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, Extranodal NK-T-Cell
3
Immunoblastic Lymphadenopathy
3
Interventions
dacetuzumab
6
blinatumomab
6
Rituximab
4
Epoetin Alfa
4
Lenalidomide
3
Dexamethasone
3
Darbepoetin alfa
3
Cyclophosphamide
3
Bortezomib
3
Therapeutics
2
Everolimus
2
Early Intervention, Educational
2
Alemtuzumab
2
venetoclax
1
vandetanib
1
tirbanibulin
1
tetulomab tetraxetan lu-177
1
ponatinib
1
plerixafor
1
pembrolizumab
1
pegaspargase
1
isatuximab
1
imetelstat
1
ibrutinib
1
fludarabine
1
ficlatuzumab
1
ferrous sulfate
1
ferric gluconate
1
ferric carboxymaltose
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoproliferative Disorders
×
Bendamustine Hydrochloride
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts